Background: Epidermodysplasia verruciformis Lewandowsky-Lutz (EV) is a rare genodermatosis, characterised by development of numerous verrucous skin lesions caused by specific genotypes of human papillomaviruses belonging to the β-papillomavirus genus. The EV loci were mapped to chromosome 2p21–p24 (EV2) and 17q25 (EV1). On chromosome 17, 2 adjacent related genes – EVER1/TMC6 and EVER2/TMC8 – were identified. We reinvestigated 2 patients originally described by Wilhelm Lutz in 1946 with the aim to document the natural course of the disease and confirm his diagnosis. Methods: PCR fragments specific for exons with short flanking intron sequences of EVER1/TMC6 and EVER2/TMC8 genes from patients’ DNA were amplified using sequence information. The single-nucleotide polymorphism (SNP) rs7208422 was studied, using restriction fragment length polymorphism analysis. Results: In the index patient, we identified a homozygous TT genotype in exon 8 of the EVER2/TMC8 gene (c.917A → T, p.N306I). The same mutation could thereafter be detected in her sister from paraffin-embedded skin. Conclusion: We have followed one of the first patients described with EV in Basel, Switzerland, in 1930 until today and demonstrated the TT genotype (SNP rs7208422) in the EVER2/TMC8 gene in this index patient and her sister. The results underline the possible relevance of SNP rs7208422 by influencing the susceptibility to β-papillomaviruses and their oncogenic potential.

1.
Itin PH, Lautenschlager S: Genodermatosis with reticulate, patchy and mottled pigmentation of the neck: a clue to rare dermatologic disorders. Dermatology 1998;197:281–290.
2.
Orth G: Genetics of epidermodysplasia verruciformis: insights into host defense against papillomaviruses. Semin Immunol 2006;18:362–374.
3.
Storey A: Papillomaviruses: death-defying acts in skin cancer. Trends Mol Med 2002;8:417–421.
4.
Lutzner MA: Epidermodysplasia verruciformis: an autosomal recessive disease characterized by viral warts and skin cancer – a model for viral oncogenesis. Bull Cancer 1978;65:169–182.
5.
Ramoz N, Taieb A, Rueda LA, Montoya LS, Bouadjar B, Favre M, Orth G: Evidence for a nonallelic heterogeneity of epidermodysplasia verruciformis with two susceptibility loci mapped to chromosome regions 2p21–p24 and 17q25. J Invest Dermatol 2000;114:1148–1153.
6.
Ramoz N, Rueda LA, Bouadjar B, Montoya LS, Orth G, Favre M: Mutations in two adjacent novel genes are associated with epidermodysplasia verruciformis. Nat Genet 2002;32:579–581.
7.
Keresztes G, Mutai H, Heller S: TMC and EVER genes belong to a larger novel family, the TMC gene family encoding transmembrane proteins. BMC Genomics 2003;4:24.
8.
Kurima K, Yang Y, Sorber K, Griffith AJ: Characterization of the transmembrane channel-like (TMC) gene family: functional clues from hearing loss and epidermodysplasia verruciformis. Genomics 2003;82:300–308.
9.
Lazarczyk M, Favre M: Role of Zn2+ ions in host-virus interactions. J Virol 2008;82:11486–11494.
10.
Lazarczyk M, Pons C, Mendoza JA, Cassonnet P, Jacob Y, Favre M: Regulation of cellular zinc balance as a potential mechanism of EVER-mediated protection against pathogenesis by cutaneous oncogenic human papillomaviruses. J Exp Med 2008;205:35–42.
11.
Lewandowsky F, Lutz W: Ein Fall einer bisher nicht beschriebenen Hauterkrankung (Epidermodysplasia verruciformis). Arch Dermatol Syph 1922;141:193–203.
12.
Fuchs H: Ein Fall von eigenartiger Dyskeratose (Epidermodysplasia verruciformis). Arch Dermatol Syph 1922;141:225–231.
13.
Lutz W: A propos de l’epidermodysplasie verruciforme. Dermatologica 1946;92:30–43.
14.
Häusermann P, Lutter S, Meigel W, Rufli T: Das Lewandowsky-Lutz-Syndrom: Die Erstbeschreibung und drei weitere Basler Fälle der Epidermodysplasia verruciformis. Z Hautkr 2002;77:176–180.
15.
Jablonska S, Milewski B: Zur Kenntnis der Epidermodysplasia verruciformis Lewandowsky-Lutz. Dermatologica 1957;115:1–22.
16.
Berthelot C, Dickerson MC, Rady P, He Q, Niroomand F, Tyring SK, Pandya AG: Treatment of a patient with epidermodysplasia verruciformis carrying a novel EVER2 mutation with imiquimod. J Am Acad Dermatol 2007;56:882–886.
17.
Bauer HM, Ting Y, Greer CE, Chambers JC, Tashiro CJ, Chimera J, Reingold A, Manos MM: Genital human papillomavirus infection in female university students as determined by a PCR-based method. JAMA 1991;265:472–477.
18.
Husnjak K, Grce M, Magdic L, Pavelic K: Comparison of five different polymerase chain reaction methods for detection of human papillomavirus in cervical cell specimens. J Virol Methods 2000;88:125–134.
19.
Harwood CA, Spink PJ, Surentheran T, Leigh IM, de Villiers EM, McGregor JM, Proby CM, Breuer J: Degenerate and nested PCR: a highly sensitive and specific method for detection of human papillomavirus infection in cutaneous warts. J Clin Microbiol 1999;37:3545–3555.
20.
Patel AS, Karagas MR, Pawlita M, Waterboer T, Nelson HH: Cutaneous human papillomavirus infection, the EVER2 gene and incidence of squamous cell carcinoma: a case-control study. Int J Cancer 2008;122:2377–2379.
21.
Hohenstein E, Rady PL, Hergersberg M, Huber AR, Tyring SK, Bregenzer T, Streit M, Itin P: Epidermodysplasia verruciformis in a HIV-positive patient homozygous for the c917A → T polymorphism in the TMC8/EVER2 gene. Dermatology 2009;218:114–118.
22.
Jablonska S, Dabrowski J, Jakubowicz K: Epidermodysplasia verruciformis as a model in studies on the role of papovaviruses in oncogenesis. Cancer Res 1972;32:583–589.
23.
Donfack J, Buchinsky FJ, Derkay CS, Steinberg BM, Choi SS, Conley SF, Meyer CM 3rd, McClay JE, Campisi P, Hu FZ, Preston RA, Abramson AL, Ehrlich GD, Post JC: Four mutations in epidermodysplasia verruciformis 1 (EVER1) gene are not contributors to susceptibility in RRP. Int J Pediatr Otorhinolaryngol 2006;70:1235–1240.
24.
Gober MD, Rady PL, He Q, Tucker SB, Tyring SK, Gaspari AA: Novel homozygous frameshift mutation of EVER1 gene in an epidermodysplasia verruciformis patient. J Invest Dermatol 2007;127:817–820.
25.
Aochi S, Nakanishi G, Suzuki N, Setsu N, Suzuki D, Aya K, Iwatsuki K: A novel homozygous mutation of the EVER1/TMC6 gene in a Japanese patient with epidermodysplasia verruciformis. Br J Dermatol 2007;157:1265–1266.
26.
Zuo YG, Ma D, Zhang Y, Qiao J, Wang B: Identification of a novel mutation and a genetic polymorphism of EVER1 gene in two families with epidermodysplasia verruciformis. J Dermatol Sci 2006;44:153–159.
27.
Tate G, Suzuki T, Kishimoto K, Mitsuya T: Novel mutations of EVER1/TMC6 gene in a Japanese patient with epidermodysplasia verruciformis. J Hum Genet 2004;49:223–225.
28.
Sun XK, Chen JF, Xu AE: A homozygous nonsense mutation in the EVER2 gene leads to epidermodysplasia verruciformis. Clin Exp Dermatol 2005;30:573–574.
29.
Orth G: Host defenses against human papillomaviruses: lessons from epidermodysplasia verruciformis. Curr Top Microbiol Immunol 2008;321:59–83.
31.
Su AI, Wiltshire T, Batalov S, Lapp H, Ching KA, Block D, Zhang J, Soden R, Hayakawa M, Kreiman G, Cooke MP, Walker JR, Hogenesch JB: A gene atlas of the mouse and human protein-encoding transcriptomes. Proc Natl Acad Sci USA 2004;101:6062–6067.
32.
Lazarczyk M, Cassonnet P, Pons C, Jacob Y, Favre M: The EVER proteins as a natural barrier against papillomaviruses: a new insight into the pathogenesis of human papillomavirus infections. Microbiol Mol Biol Rev 2009;73:348–370.
33.
Androphy EJ, Dvoretzky I, Lowy DR: X-linked inheritance of epidermodysplasia verruciformis: genetic and virologic studies of a kindred. Arch Dermatol 1985;121:864–868.
34.
McDermott DF, Gammon B, Snijders PJ, Mbata I, Phifer B, Howland Hartley A, Lee CC, Murphy PM, Hwang ST: Autosomal dominant epidermodysplasia verruciformis lacking a known EVER1 or EVER2 mutation. Pediatr Dermatol 2009;26:306–310.
35.
Tanigaki T, Kanda R, Sato K: Epidermodysplasia verruciformis (L-L, 1922) in a patient with systemic lupus erythematosus. Arch Dermatol Res 1986;278:247–248.
36.
Gross G, Ellinger K, Roussaki A, Fuchs PG, Peter HH, Pfister H: Epidermodysplasia verruciformis in a patient with Hodgkin’s disease: characterization of a new papillomavirus type and interferon treatment. J Invest Dermatol 1988;91:43–48.
37.
Barr BB, Benton EC, McLaren K, Bunney MH, Smith IW, Blessing K, Hunter JA: Papillomavirus infection and skin cancer in renal allograft recipients. Lancet 1989;ii:224–225.
38.
Hultgren TL, Srinivasan SK, DiMaio DJ: Epidermodysplasia verruciformis occurring in a patient with human immunodeficiency virus: a case report. Cutis 2007;79:307–311.
39.
Lutzner M, Croissant O, Ducasse MF, Kreis H, Crosnier J, Orth G: A potentially oncogenic human papillomavirus (HPV-5) found in two renal allograft recipients. J Invest Dermatol 1980;75:353–356.
40.
Rogers HD, Macgregor JL, Nord KM, Tyring S, Rady P, Engler DE, Grossman ME: Acquired epidermodysplasia verruciformis. J Am Acad Dermatol 2009;60:315–320.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.